Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens exercised performance share units that converted into 8,500 shares of common stock on April 2, 2026 after a specified regulatory milestone was achieved.
Each performance share unit represented a contingent right to receive one share of common stock, and the grant was originally made on March 1, 2024. Following this vesting and exercise, Gheuens sold 2,940 shares of common stock at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, she directly owns 80,277 common shares, which include 311 shares purchased through the company’s employee stock purchase plan.
Agios Pharmaceuticals' Chief Financial Officer Cecilia Jones exercised performance share units and sold shares primarily to cover taxes. She converted 8,500 performance share units into 8,500 shares of common stock after a specified regulatory milestone was determined to have been met on April 2, 2026. On the same date, 3,141 shares were sold at $34.71 per share to satisfy tax withholding obligations under durable automatic sale instructions included in her March 1, 2024 performance share unit agreement, which is structured to be consistent with the Rule 10b5-1(c) affirmative defense. After these transactions, she directly held 54,998 shares of common stock, including 311 shares acquired through the company’s employee stock purchase plan.
Agios Pharmaceuticals Chief Commercial Officer Tsveta Milanova reported a vesting and tax-related sale of shares. On April 2, 2026, 8,500 performance share units were exercised into 8,500 shares of common stock at $0.00 per share, reflecting the vesting of performance-based equity compensation tied to a specified regulatory milestone.
On the same date, 3,262 shares of common stock were sold at $34.71 per share to cover tax withholding obligations, executed under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, Milanova directly owned 46,829 shares of Agios common stock.
Agios Pharmaceuticals executive Krishnan Viswanadhan reported an exercise-and-sell transaction tied to performance share units (PSUs). On April 2, 2026, 8,100 PSUs converted into 8,100 shares of common stock at $0.00 per share when a specified regulatory milestone was achieved.
On the same date, 2,959 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he held 10,282 shares of Agios common stock directly.
Agios Pharmaceuticals Chief Executive Officer Brian Goff reported vesting and settlement of performance share units tied to regulatory milestones, resulting in the delivery of 39,028 shares of common stock. On the same date, 19,068 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these compensation-related transactions, he holds 184,508 common shares directly.
AGIO reported Form 144 sale/transfer activity tied to executive restricted stock units. The filing lists 19,068 shares associated with vesting of RSUs on 04/02/2026 and discloses a prior sale of 18,055 shares on 03/02/2026 for $522,873.
AGIO submitted a Form 144 notice to sell 3,141 shares of Common Stock tied to the vesting of Restricted Stock Units on 04/02/2026. The excerpt also shows a prior sale by Cecilia Jones of 5,035 shares on 03/02/2026.
AGIO Therapeutics reported a notice under Rule 144 for common stock related to an insider transaction. The filing shows 2,959 shares tied to the vesting of Restricted Stock Units on 04/02/2026. The filing also records that Krishnan Viswanadhan had 2,959 shares listed under "Securities Sold During The Past 3 Months" with an associated dollar figure of $82,260.00 dated 03/05/2026.
AGIO affiliate filed a Form 144 notice for proposed sales of Common Stock tied to the vesting of restricted stock units on 04/02/2026. The filing lists quantities and dollar values for recent sales by Tsveta Milanova, including 2,868 shares ($83,057.00) on 03/02/2026 and 2,872 shares ($77,601.00) on 01/05/2026.
AGIO Pharmaceuticals reported a proposed sale of 2,940 shares of Common Stock under a Form 144 notice dated 04/02/2026, arising from the vesting of Restricted Stock Units. The filing also reports a prior sale of 4,055 shares on 03/02/2026.
The Form 144 lists the broker Morgan Stanley Smith Barney LLC and shows monetary figures adjacent to the share entries. The filing documents a routine affiliate sale notice tied to RSU vesting.